You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.


The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline
 
[the_ad_placement id="main-ldb-public"]
[the_ad_placement id="main-ldb-mobile-public"]

You are reading 1 of 2 free-access articles allowed for 30 days

European breast cancer trial opens in Ireland

By Dermot - 13th Jul 2016 | 2 views

The trial will investigate the added benefit of combining the new drug palbociclib with an existing drug fulvestrant. Fulvestrant is currently used to treat postmenopausal women with hormone receptor (HR)-positive<a title=”This external link will open in a new window” href=”https://mail.securesuite.io/webapp/index.php#_ftn1″ target=”_blank”>[1]</a> advanced breast cancer.

Palbociclib is approved in the USA by the US Food and Drug Administration (FDA) but is not yet approved in Europe for treating HR-positive, HER2-negative advanced breast cancer. As a result Irish patients who receive this new drug combination during the trial will be the first in Ireland to do so as a first line treatment for their advanced breast cancer.

As with all Cancer Trials Ireland trials, participants will have free access to the drugs used during the trial and the trial has been approved by Ireland’s Health Products Regulatory Authority.

The new drug combination will be tested among postmenopausal women with advanced breast cancer, who have had at least five years of standard hormonal treatment and have remained disease free for more than 12 months, but have subsequently suffered a relapse or are diagnosed with new cancer which has spread to other parts of their body.

The trial is a randomised double blind study, which means that half of the participants will receive the new drug combination (fulvestrant and palbociclib) and half will receive the existing standard of care i.e. fulvestrant on its own. Patients, their doctors and the study’s research team (including nurses) will not know which patients receive which combination.

 

The trial is expected to continue over the next four years with eight hospitals in Ireland participating. These include St. James’s Hospital, Dublin; St Vincent’s University Hospital, Dublin; Mater Hospital, Dublin; Beaumont Hospital, Dublin; Bon Secours Hospital, Cork; University Hospital Galway, University Hospital Waterford and University Hospital Limerick.

The study’s Principal Investigator in Ireland is Dr Miriam O’Connor, Consultant Medical Oncologist, at University Hospital Waterford.

Dr O’Connor said that the growing data about the clinical activity of fulvestrant, together with the efficacy data for palbociclib, support their combined use in women with HR-positive, HER2-negative advanced breast cancer.

 “There is an unmet need for effective, non-toxic therapy for women with this type of breast cancer. We hope the study will provide new data to assist physicians in their management of patients with advanced breast cancer and help us find more answers,” she said.

Leave a Reply

[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]
Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

[the_ad_placement id="main-mpu-public"]
Most Read
[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]